{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:21:14Z","timestamp":1787509274744,"version":"build-2736575974"},"reference-count":27,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"French Health Ministry","award":["PHRC 2022"],"award-info":[{"award-number":["PHRC 2022"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,8,1]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Several randomised controlled trials have demonstrated that novel oral anticoagulants are safer compared with vitamin K antagonists for the management of non-valvular atrial fibrillation (NVAF) to prevent thromboembolic events in the general population. There is a growing interest in the use of apixaban in patients with end-stage renal disease (ESRD) undergoing peritoneal dialysis (PD) but there is a lack of randomised data in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>APIDP2 is a prospective parallel, randomised, open-label, blinded endpoint trial involving patients with ESRD undergoing chronic PD who have NVAF. A total of 178 participants will be recruited from 20 French PD centres. Eligible patients will be randomly assigned to receive either apixaban at a reduced dose of 2.5 mg two times per day (dose determined with the previous pharmacokinetic study APIDP1) or dose-adjusted to international normalised ratio (INR) target (2\u20133) coumadin therapy. Anticoagulation to prevent thromboembolic events will be initiated or changed according to the randomisation for a duration of 1 year. The primary outcome is a major or clinically relevant non-major bleeding from randomisation up to month 12, assessed according to the International Society on Thrombosis and Haemostasis Score. Secondary outcomes encompass an efficacy composite criterion combining stroke or transient ischaemic attack (TIA), cardiovascular death and thrombosis including myocardial infarction cumulated at 12 months. Bleeding events will be also classified according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) and Thrombolysis In Myocardial Infarction (TIMI) criteria and pharmacodynamics outcomes will evaluate the time within the INR target range of 2\u20133 in the warfarin arm over 1 year, and anti-Xa apixaban activity in case of bleeding events and at 1 month, 6 months and 12 months of follow-up in the apixaban arm. To demonstrate that apixaban is safer than warfarin at 1 year, assuming two interim analyses after 60 and 118 patients, a bilateral alpha risk of 5% and a power of 80%, 178 patients are needed in this randomised trial (effect size found from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Study among patients with creatinine clearance 25\u201330 ml\/min), that is, 89 patients per group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study has been approved by the ethics committee Comit\u00e9 de Protection des Personnes Sud Est III \u2013 Lyon - FRANCE, CT number 2023-507544-37-00. Written informed consent is required for each participant. Findings will be presented at scientific meetings and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06045858\">NCT06045858<\/jats:ext-link>\n                      ; European Clinical Trial System, CT number 2023-507544-37-00.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-089353","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T04:00:49Z","timestamp":1726891249000},"page":"e089353","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non-valvular atrial fibrillation: protocol for a prospective, randomised, open-label, blinded endpoint trial (APIDP2)"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct06045858","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Maxence","family":"Ficheux","sequence":"first","affiliation":[{"name":"Nephrology, CUMR, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0301-1058","authenticated-orcid":false,"given":"Laure","family":"Peyro-Saint-Paul","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Biostatistics, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doroth\u00e9e","family":"Balayn","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Biostatistics, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Lecrux","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Biostatistics, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Brossier","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Biostatistics, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Morin","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Biostatistics, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lanot","sequence":"additional","affiliation":[{"name":"Nephrology, CUMR, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Peron","sequence":"additional","affiliation":[{"name":"Cardiology, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Boulanger","sequence":"additional","affiliation":[{"name":"Neurology, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Brionne","sequence":"additional","affiliation":[{"name":"Biological Hematology, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2170-8983","authenticated-orcid":false,"given":"Farzin","family":"Beygui","sequence":"additional","affiliation":[{"name":"Cardiology, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Parienti","sequence":"additional","affiliation":[{"name":"Biostatistics and Clinical Research Unit (UBRC), CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lobbedez","sequence":"additional","affiliation":[{"name":"Nephrology, CUMR, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"B\u00e9chade","sequence":"additional","affiliation":[{"name":"Nephrology, CUMR, CHU Caen Normandie, Caen, Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"2025120600353900000_14.9.e089353.1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000535546","article-title":"Anticoagulation in Patients with Chronic Kidney Disease","volume":"55","author":"Elenjickal","year":"2024","journal-title":"Am J Nephrol"},{"key":"2025120600353900000_14.9.e089353.2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139X.2003.16048.x"},{"key":"2025120600353900000_14.9.e089353.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212237","article-title":"Evaluation of hemostasis in patients with end-stage renal disease","volume":"14","author":"G\u00e4ckler","year":"2019","journal-title":"PLoS One"},{"key":"2025120600353900000_14.9.e089353.4","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01810407"},{"key":"2025120600353900000_14.9.e089353.5","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"key":"2025120600353900000_14.9.e089353.6","article-title":"Calciphylaxis in the Setting of Hemodialysis, Liver Cirrhosis, and Warfarin Therapy for Atrial Fibrillation: An Argument for Alternative Anti-Embolic Therapy","volume":"12","author":"Medepalli","year":"2020","journal-title":"Cureus"},{"key":"2025120600353900000_14.9.e089353.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062779"},{"key":"2025120600353900000_14.9.e089353.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054990"},{"key":"2025120600353900000_14.9.e089353.9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020111566"},{"key":"2025120600353900000_14.9.e089353.10","doi-asserted-by":"crossref","unstructured":"Fatima H , Nwankwo I , Anam M , et al . Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review. Cureus 2022. doi:10.7759\/cureus.30230","DOI":"10.7759\/cureus.30230"},{"key":"2025120600353900000_14.9.e089353.11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1005742","article-title":"Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025120600353900000_14.9.e089353.12","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s40620-022-01413-x","article-title":"A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease","volume":"35","author":"Parker","year":"2022","journal-title":"J Nephrol"},{"key":"2025120600353900000_14.9.e089353.13","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1007\/s12325-023-02544-8","article-title":"Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency","volume":"40","author":"Hahn","year":"2023","journal-title":"Adv Ther"},{"key":"2025120600353900000_14.9.e089353.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035418"},{"key":"2025120600353900000_14.9.e089353.15","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.03.007"},{"key":"2025120600353900000_14.9.e089353.16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.123.065614","article-title":"Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease","volume":"148","author":"Xu","year":"2023","journal-title":"Circulation"},{"key":"2025120600353900000_14.9.e089353.17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.amjcard.2023.08.116","article-title":"Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation in End-Stage Renal Disease on Hemodialysis: A Meta-Analysis of Randomized Control Trials","volume":"206","author":"Faisaluddin","year":"2023","journal-title":"Am J Cardiol"},{"key":"2025120600353900000_14.9.e089353.18","doi-asserted-by":"crossref","first-page":"1261183","DOI":"10.3389\/fcvm.2023.1261183","article-title":"The safety and efficacy of direct oral anticoagulants among chronic kidney disease patients on dialysis with non-valvular atrial fibrillation: a meta-analysis","volume":"10","author":"Mapili","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2025120600353900000_14.9.e089353.19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehaa945","article-title":"Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2025120600353900000_14.9.e089353.20","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.628"},{"key":"2025120600353900000_14.9.e089353.21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016090980"},{"key":"2025120600353900000_14.9.e089353.22","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfad087","article-title":"Effect of peritoneal dialysis in end-stage renal disease on apixaban pharmacokinetics","volume":"38","author":"Peyro-Saint-Paul","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025120600353900000_14.9.e089353.23","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100646","article-title":"Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients","volume":"5","author":"Fung","year":"2023","journal-title":"Kidney Med"},{"key":"2025120600353900000_14.9.e089353.24","doi-asserted-by":"crossref","first-page":"100699","DOI":"10.1016\/j.xkme.2023.100699","article-title":"Apixaban Dosing in Patients With Kidney Failure Treated With Peritoneal Dialysis","volume":"5","author":"Lidgard","year":"2023","journal-title":"Kidney Med"},{"key":"2025120600353900000_14.9.e089353.25","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"2025120600353900000_14.9.e089353.26","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.19.2231"},{"key":"2025120600353900000_14.9.e089353.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.11.1356"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-089353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T08:35:50Z","timestamp":1765010150000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-089353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,20]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bmjopen-2024-089353"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-089353","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}